Despite the Name, Rare Diseases are Not So Rare

Despite the Name, Rare Diseases are Not So Rare

If you are not one of the millions of patients and families with a rare disease, you may think they have a low social or economic impact. On the contrary, collectively, they affect more than 350 million patients globally, many of whom are children. Death or reduced lifespan is a common outcome for patients with a rare disease, and rare diseases cause 28% of all neonatal intensive care unit deaths. The signs and symptoms vary between patients and are shared among rare diseases, so it can take up to 8 years to get an accurate diagnosis. Meanwhile, families struggle to care for their loved one with the illness while meeting their day-to-day obligations to work and each other. The stories of people living with a rare disease are elevated annually during February and on Rare Disease Day, the last day of the month. Knowledge starts with learning the definition of a rare disease and understanding how it applies to the legion of conditions and ailments represented by this community.

Learn more in my post at Rare Disease Day. See the source of my facts and learn more from these patient advocacy group sites:

Global Genes

National Organization for Rare Disorders

Rare Disease Day



要查看或添加评论,请登录

KATRINA ROGERS的更多文章

  • Contemplating Consulting? Here Are My Thoughts

    Contemplating Consulting? Here Are My Thoughts

    Like many, I subscribe to multiple newsletters to access different sources and learn from other voices. One of these…

  • Make or Buy? Outsourcing as a Strategic Choice

    Make or Buy? Outsourcing as a Strategic Choice

    BONUS: I host a live chat in Substack every Friday at 9am PST. This is exclusive to my Substack subscribers! Questions?…

  • Four Points of Startup Readiness

    Four Points of Startup Readiness

    I speak with many startup founders every week. Most work in drugs, medical devices, diagnostic tests, or digital health…

  • Understanding Dilutive Funding – Part 2

    Understanding Dilutive Funding – Part 2

    In December, we reviewed non-dilutive funding sources in a two-part article, including bootstrapping, friends and…

  • My Reading List from 2024

    My Reading List from 2024

    Welcome to my reading list from 2024! I’ve been pleasantly surprised by my reader’s response to previous book…

    4 条评论
  • Understanding Dilutive Funding – Part 1

    Understanding Dilutive Funding – Part 1

    Last month, we reviewed non-dilutive funding sources in a two-part article, including bootstrapping, friends and family…

    2 条评论
  • What Is Non-Dilutive Funding? Part 2

    What Is Non-Dilutive Funding? Part 2

    We are discussing sources of non-dilutive funding this month. Simply put, non-dilutive funding is startup money that…

  • The Funding Expansion

    The Funding Expansion

    This month, I wrote an article summarizing and commenting on the content of two reports from Rise of the Rest, a…

  • What Is Non-Dilutive Funding? Part 1

    What Is Non-Dilutive Funding? Part 1

    We receive lots of questions about how to start a company to commercialize a new therapy. Many of those questions are…

    3 条评论
  • Katrina in the Bullpen

    Katrina in the Bullpen

    You may have seen my LinkedIn posts about the Bullpen and wondered, “What is this group, and why is Katrina involved?”…

    2 条评论

社区洞察

其他会员也浏览了